Epithalon vs Glutathione
Epithalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, derived from the bovine pineal extract preparation Epithalamin, and its published work reports telomerase induction in cultured human cells, circadian and pineal gene regulation, antioxidant effects and lifespan extension in flies and rodents. Glutathione is the endogenous tripeptide glutamate-cysteine-glycine, the principal intracellular thiol antioxidant and redox buffer, with a human literature spanning oral and intravenous pharmacokinetics, dermatological pigmentation trials and precursor repletion strategies. The two are set alongside each other because both are sold as antioxidant longevity compounds. No study has ever administered the tetrapeptide and glutathione together. The closest thing to a direct comparison is a 1997 Russian in vitro chemiluminescence assay that measured melatonin, glutathione and Epithalamin, the pineal extract rather than the synthetic peptide, in the same experiment. Everything else that engages both compounds either measured glutathione-dependent enzymes after dosing the peptide, or discussed the two within one review.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published study has administered the Ala-Glu-Asp-Gly tetrapeptide and glutathione within one design, in any model. Two lines of work come close without meeting that bar. The first is a 1997 Russian report from Diatlov and colleagues that compared the antioxidant properties of melatonin, glutathione and Epithalamin in a luminol-dependent chemiluminescence assay; the substance tested there was the bovine pineal extract from which the tetrapeptide was subsequently derived, not the tetrapeptide itself, and only the Russian-language record is indexed. The second is a group of rodent studies from Kozina and colleagues at the St Petersburg Institute of Bioregulation and Gerontology, which administered Epitalon or Epithalamin to old or hypoxia-exposed rats and measured the activity of glutathione-dependent enzymes, principally glutathione peroxidase and glutathione-S-transferase, among their antioxidant endpoints. Those studies engage the glutathione system as a readout rather than as a comparator: glutathione itself was never given. The remaining publications naming both are longevity and antioxidant reviews that discuss each substance separately within a shared framing.
The 8 publications that cover both
- 01In vitro1997· Russian (no English abstract)
[Comparison of the antioxidant properties of melatonin, epithalamin, and glutathione by the method of luminol-dependent chemiluminescence in vitro]
Diatlov RV, et al. · Doklady Akademii Nauk · luminol-dependent chemiluminescence assay comparing melatonin, the bovine pineal extract preparation Epithalamin and glutathione in vitro
The study placed melatonin, Epithalamin and glutathione in a single in vitro chemiluminescence assay of antioxidant activity, and is the only located publication that measured a pineal peptide preparation and glutathione under the same conditions. The substance tested was the pineal extract Epithalamin rather than the synthetic Ala-Glu-Asp-Gly tetrapeptide. Only the Russian-language record is indexed and no English abstract is available, so the reported outcome cannot be verified from the PubMed record.
- 02Animal in vivo2007
Antioxidant properties of geroprotective peptides of the pineal gland
Kozina LS, et al. · Archives of Gerontology and Geriatrics · old rats given the pineal extract Epithalamin or the Ala-Glu-Asp-Gly tetrapeptide; total antioxidant and antiradical activity plus superoxide dismutase, glutathione peroxidase and glutathione-S-transferase activity measured in blood serum, liver and brain
Both pineal preparations were reported to possess antioxidant properties that in some cases exceeded those of melatonin, and the assay panel used to establish this was built on glutathione-dependent enzymes alongside superoxide dismutase. The authors described a mechanism distinct from melatonin's, including stimulation of superoxide dismutase and ceruloplasmin expression and possible binding of transition metals. Glutathione itself was not administered and served only as the basis of the enzyme readouts.
- 03Animal in vivo2007
Effects of bioactive tetrapeptides on free-radical processes
Kozina LS · Bulletin of Experimental Biology and Medicine · Wistar rats injected with epithalon or cortagen; lipid peroxidation products, oxidative protein modification and antioxidant activity measured in serum and cerebral cortex, with glutathione peroxidase and superoxide dismutase among the indexed endpoints
Injections of epithalon and cortagen decreased the content of lipid peroxidation products and reduced oxidative modification of proteins in rat serum and cerebral cortex, alongside a reported change in serum and cortical antioxidant activity. Glutathione peroxidase was among the enzymes indexed for the study. Glutathione was not given as a treatment and no comparator antioxidant arm was included.
- 04Animal in vivo2008· Russian (English abstract)
[Investigation of antihypoxic properties of short peptides]
Kozina LS · Advances in Gerontology (Uspekhi Gerontologii) · hypobaric hypoxia model in rats comparing the short peptides vilon, epitalon, vesugen and pinealon, with prenatal hypoxia experiments and antioxidant enzyme endpoints including glutathione peroxidase
All four short peptides showed antihypoxic properties in the hypobaric hypoxia model, with pinealon reported as the most pronounced. The author attributed the increase in neuronal resistance to hypoxic stress less to suppression of reactive oxygen species than to stimulation of the internal antioxidant enzyme system, of which the glutathione-dependent enzymes form part, and to possible limitation of N-methyl-D-aspartate excitotoxicity.
- 05Review2025
Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties
Araj SK, et al. · International Journal of Molecular Sciences · narrative review covering approximately 25 years of Epitalon literature
The review recorded that in a glycerol-induced rodent model of acute kidney failure Epitalon increased diuresis, decreased protein excretion and increased the activity of catalase and glutathione peroxidase relative to untreated animals with acute kidney failure. The engagement with glutathione is confined to the glutathione-dependent enzyme system rather than to any comparison against glutathione as a treatment, and the authors stated that substantial gaps remain in the understanding of the peptide's molecular mechanism and clinical relevance.
- 06Review2026
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Mavrych V, et al. · Frontiers in Aging · narrative review of nine therapeutic peptides in aging research, with searches of PubMed, Scopus and regulatory databases from inception through January 2026
The review reported that animal studies suggest epitalon increases the activity of antioxidant enzymes including superoxide dismutase and glutathione peroxidase, and that lifespan in rodent longevity studies was extended by 12 to 24 per cent. It placed epitalon among investigational peptides whose rationale rests largely on preclinical data and concluded that this class requires validation through well-designed clinical trials before therapeutic claims can be made.
- 07Review2024
Biomedicines in Longevity and Aging the Quest to Resist Biological Decline
Palmer RD · Biomedicine (Taipei) · narrative review of interventions proposed against nine pathways of biological ageing
The review discussed both substances within one account of longevity interventions. Epithalon was described as a tetrapeptide inducing expression of the telomerase catalytic subunit and associated enzymatic activity, and glutathione was described among the endogenous antioxidants that decline with age. The review noted that orally administered glutathione is poorly absorbed because of rapid hydrolysis by gamma-glutamyltransferase in intestinal mucosa, hepatocytes and cholangiocytes, and that N-acetylcysteine is used as a precursor instead. No experiment compared the two.
- 08Review2014
Effect of antioxidants supplementation on aging and longevity
Sadowska-Bartosz I, Bartosz G · BioMed Research International · review of exogenous antioxidant supplementation and lifespan across model organisms, including yeast, Caenorhabditis elegans, Drosophila melanogaster and rodents
Both substances appeared in the same survey. Epitalon was listed as a synthetic tetrapeptide with antioxidant activity that increased Drosophila lifespan by 11 to 16 per cent, and reduced glutathione was listed among hydrophilic antioxidants that prolonged nematode lifespan when delivered in liposomes while conventional oral delivery produced no longevity effect. The authors argued that lifespan effects frequently do not track antioxidant potency and are often due to indirect action unrelated to the antioxidant properties of the compound given.
Side by side.
| Epithalon | Glutathione | |
|---|---|---|
| Evidence maturity | Early clinical | Early clinical |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 8 | 9 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | A synthetic tetrapeptide, Ala-Glu-Asp-Gly, designed as the active fragment of Epithalamin, a bovine pineal gland extract. It is not described as an endogenous human peptide in its own right. | An endogenous tripeptide, glutamate-cysteine-glycine, synthesised in every human cell and functioning as the principal intracellular thiol antioxidant and redox buffer. Its physiological role is established independently of any product. |
| Mechanism as described in the literature | Induction of telomerase activity and telomere elongation in cultured human cells, modulation of circadian and pineal gene expression, and stimulation of antioxidant enzyme activity, with molecular docking proposed as the basis for an epigenetic action on histones and DNA. | Direct redox buffering as the substrate of glutathione peroxidase and glutathione-S-transferase, maintenance of the GSH to GSSG ratio, and detoxification of electrophiles. The therapeutic question is not mechanism but whether administered glutathione raises intracellular pools. |
| Size of the evidence base | Fifteen verified publications in the research entry here, of which eight are in vitro studies and only two are human. The largest human report was an open, non-randomised follow-up that used the pineal extract rather than the tetrapeptide. | Fifteen verified publications, of which ten are human clinical trials and two are systematic reviews. The human work covers pharmacokinetics, dermatology, Parkinson's disease and precursor repletion. |
| Best-characterised finding | A 2003 report that adding the tetrapeptide to human fetal fibroblast cultures at the Hayflick limit induced telomerase activity and telomere elongation, with treated cultures undergoing additional population doublings. It remains the foundational claim for the compound. | A six-month randomised double-blind placebo-controlled trial in 54 non-smoking adults in which oral glutathione raised erythrocyte, plasma and lymphocyte glutathione by roughly 30 to 35 per cent and buccal cell glutathione considerably more, with values returning to baseline after a one-month washout. |
| Human data | Two studies, neither randomised or placebo-controlled: a buccal epithelium study in subjects with disturbed melatonin secretion, and a 6-to-8-year open observational follow-up of elderly cohorts that used the pineal extract preparations rather than the synthetic peptide. | Randomised controlled trials across several indications, including crossover pharmacokinetic trials of micellar, liposomal, tablet and orally dissolving film formulations, a placebo-controlled skin-lightening trial in 60 adults, and a placebo-controlled intranasal trial in 45 people with Parkinson's disease that showed no advantage over placebo. |
| Evidence maturity | Early clinical in name only. No registered, placebo-controlled randomised trial of the synthetic tetrapeptide has been published, and the human reports that exist are open-label and used the extract rather than the peptide. | Early clinical with real controlled data, but small and heterogeneous. Trials typically ran from four weeks to six months in fewer than 60 participants, and results were negative for direct administration in Parkinson's disease. |
| Safety signals reported | No controlled safety dataset exists. The entry records that any oncological risk arising from telomerase induction is uncharacterised, and independent in vitro work reported telomere lengthening in breast cancer cell lines through alternative lengthening of telomeres. | Documented. Reviews describe anaphylaxis and hepatotoxicity associated with intravenous administration, and one participant in a phase IIb intranasal trial developed cardiomyopathy. A 30-day oral safety phase reported no significant change in liver enzymes or creatinine. |
| Basis of most marketing claims | Extrapolation from cell-culture telomerase data and from rodent and Drosophila lifespan studies, most from a single research group, to human anti-ageing outcomes that no controlled trial has measured. | Extrapolation from formulation pharmacokinetics and from short dermatological trials to systemic anti-ageing outcomes. Intravenous administration for cosmetic or longevity purposes is not approved in any major jurisdiction and controlled efficacy data for infusion are essentially limited to one placebo-controlled dermatology study. |
And what it does not.
The published record does not establish how these two compounds compare, because the synthetic tetrapeptide and glutathione have never been given in the same experiment. The closest approach is a 1997 in vitro chemiluminescence assay that ran glutathione against the bovine pineal extract Epithalamin rather than the peptide, and a series of rodent studies from one St Petersburg group that measured glutathione peroxidase and glutathione-S-transferase activity as readouts after dosing the peptide. What the separate literatures support is unequal rather than contradictory. Glutathione has genuine randomised human data on whether administration raises body stores, on skin pigmentation and on Parkinson's disease, and that data includes clear negatives and documented harms with intravenous use. Epithalon has an in vitro telomerase result, animal lifespan reports concentrated in a single group, and no registered placebo-controlled trial of the tetrapeptide in humans at all. Neither has controlled evidence of an effect on human ageing, and neither has a dose-response established for that purpose.
Common questions.
- Has any experiment given Epithalon and glutathione to the same subjects?
None has. Searches of PubMed and Europe PMC across the names Epithalon, Epitalon, AEDG, Ala-Glu-Asp-Gly and Epithalamin, combined with glutathione and its abbreviations, returned no study administering both. A 1997 Russian in vitro assay compared melatonin, glutathione and Epithalamin, but Epithalamin is the bovine pineal extract from which the tetrapeptide was derived rather than the peptide itself, and only the Russian-language record is indexed. Every other publication naming both either used glutathione-dependent enzymes as a readout or discussed the two separately within one review.
- What does it mean when a study reports that Epithalon raised glutathione peroxidase?
It means the enzyme's activity was measured after the peptide was administered, not that glutathione was given or compared. Glutathione peroxidase and glutathione-S-transferase use glutathione as a substrate, so their activity is a standard readout of the endogenous antioxidant system. Rodent studies from the St Petersburg group used exactly this panel, alongside superoxide dismutase and total antiradical activity, to argue that the pineal peptides act on the antioxidant defence system. The design cannot say anything about how the peptide performs relative to glutathione supplementation.
- Which of the two has randomised human evidence?
Glutathione does. Its entry contains randomised crossover pharmacokinetic trials of micellar, liposomal, tablet and orally dissolving film formulations, a six-month randomised placebo-controlled trial of body stores in 54 adults, a placebo-controlled skin-lightening trial in 60 adults and a double-blind placebo-controlled intranasal trial in 45 people with Parkinson's disease. Epithalon has no registered, placebo-controlled randomised trial of the synthetic tetrapeptide; its two human reports were open in design and the larger one used the pineal extract preparation rather than the peptide.
- Do the two share an antioxidant mechanism?
Only at a general level, and the descriptions differ in kind. Glutathione is itself the reducing substrate of a defined enzyme system, so its antioxidant role is direct and biochemically specified. Epithalon is reported to raise the activity of antioxidant enzymes rather than to act as a reductant, with the pineal literature describing stimulation of superoxide dismutase and ceruloplasmin expression and possible binding of transition metals. A 2014 review of antioxidant supplementation and lifespan noted that longevity effects in model organisms frequently do not track antioxidant potency at all.
- Which compound has better-documented risks?
Glutathione, because it has been used enough to accumulate reports. Reviews of dermatological use describe anaphylaxis and hepatotoxicity associated with intravenous administration, one participant in a phase IIb intranasal Parkinson's trial developed cardiomyopathy, and a critical review of intravenous longevity infusions concluded that the practice is not supported by adequate controlled data. For Epithalon no controlled safety dataset exists, and the open question raised in its own research entry is whether telomerase induction carries oncological risk, which has not been characterised.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.